BioPoly

About BioPoly

BioPoly is an orthopedic medical device company that addresses the market for cartilage defect treatments, positioning itself between biologic solutions and total joint replacement. The company was established in 2006, as a spin-off from the medical technology incubator Schwartz Biomedical, LLC, founded by Dr. Herb Schwartz and Sheila Schwartz. Dr. Schwartz, with a Ph.D. in Biomechanical Engineering and over 50 patents, identified the market need, while Sheila Schwartz, a pharmacist, provided the initial angel investment and now serves as COO, managing operations, regulatory, and finance. BioPoly's core technology, which originated from research at Colorado State University, is a patented microcomposite biomaterial that combines ultra-high molecular weight polyethylene (UHMWPE) with hyaluronic acid (HA). This combination creates a self-lubricating, durable, and cartilage-friendly implant material designed to mimic the function of natural cartilage.

The company's business model revolves around the development, manufacturing, and sale of these orthopedic implants to healthcare professionals. BioPoly targets a patient demographic often considered too young for total joint replacements but for whom biologic treatments may not be ideal. Revenue is generated through the sale of its implant systems. The company has raised over $19 million through a combination of grants and private equity offerings to fund product development, clinical studies, and market expansion. Based in Fort Wayne, Indiana, BioPoly operates as an ISO 13485 certified manufacturer.

BioPoly's product portfolio includes partial resurfacing implants designed to replace only the damaged cartilage, facilitating a less invasive procedure and quicker recovery. The company's flagship material is utilized across its product lines for the knee, toe, and elbow. The implants for the Great Toe, Lesser Toe, and Radial Head have received FDA 510(k) clearance for sale in the U.S. market. The BioPoly Knee System, which has been available in Europe since 2012 under a CE Mark, received FDA Breakthrough Device Designation in 2023 and is currently undergoing an FDA-approved clinical study in the United States. The material's unique properties allow it to articulate with surrounding natural cartilage, a distinct advantage over traditional all-metal implants that can cause wear on opposing cartilage surfaces.